The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver
By:
References
- J. Matsui, Y. Yamamoto, Y. Funahashi, A. Tsuruoka, T. Watanabe, T. Wakabayashi, T. Uenaka and M. Asada, E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition, <em>Int. J. Cancer</em> <bold>122</bold> (2008) 664–671; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1002/ijc.23131" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1002/ijc.23131</a>">https://doi.org/10.1002/ijc.23131</ext-link>
- Y. Yamamoto, J. Matsui, T. Matsushima, H. Obaishi, K. Miyazaki, K. Nakamura, O. Tohyama, T. Semba, A. Yamaguchi, S. S. Hoshi, F. Mimura, T. Haneda, Y. Fukuda, J. Kamata, K. Takahashi, M. Matsukura, T. Wakabayashi, M. Asada, K. Nomoto, T. Watanabe, Z. Dezso, K. Yoshimatsu, Y. Funahashi and A. Tsuruoka, Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage, <em>Vasc. Cell</em> <bold>6</bold> (2014) Article ID 18 (19 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1186/2045-824X-6-18" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1186/2045-824X-6-18</a>">https://doi.org/10.1186/2045-824X-6-18</ext-link>
- K. Ikuta, S. Yano, V. T. Trung, M. Hanibuchi, H. Goto, Q. Li, W. Wang, T. Yamada, H. Ogino, S. Kakiuchi, H. Uehara, Y. Sekido, T. Uenaka, Y. Nishioka and S. Sone, E7080, a Multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles, <em>Clin. Cancer Res.</em> <bold>15</bold> (2009) 7229–7237; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1158/1078-0432.CCR-09-1980" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1158/1078-0432.CCR-09-1980</a>">https://doi.org/10.1158/1078-0432.CCR-09-1980</ext-link>
- A. Nair, S. J. Lemery, J. Yang, A. Marathe, L. Zhao, H. Zhao, X. Jiang, K. He, G. Ladouceur, A. K. Mitra, L. Zhou, E. Fox, S. Aungst, W. Helms, P. Keegan and R. Pazdur, FDA Approval Summary: Lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer, <em>Clin. Cancer Res.</em> <bold>21</bold> (2015) 5205–5208; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1158/1078-0432.CCR-15-1377" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1158/1078-0432.CCR-15-1377</a>">https://doi.org/10.1158/1078-0432.CCR-15-1377</ext-link>
- A. Nair, K. Reece, M. B. Donoghue, W. (Vivian) Yuan, L. Rodriguez, P. Keegan and R. Pazdur, FDA Supplemental Approval Summary: Lenvatinib for the treatment of unresectable hepatocellular carcinoma, <em>The Oncologist</em> <bold>26</bold> (2021) e484–e491; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1002/onco.13566" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1002/onco.13566</a>">https://doi.org/10.1002/onco.13566</ext-link>
- L. Fala, Lenvima (lenvatinib) approved in combination with everolimus for patients with advanced renal-cell carcinoma, <em>Oncol. Pract. Manag.</em> <bold>7</bold> (2017); Retrieved from <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://oncpracticemanagement.com/issues/2017/february-2017-vol-7-no-2/905-lenvima-lenvatinib-approved-in-combination-with-everolimus-for-patients-with-advanced-renal-cell-carcinoma">https://oncpracticemanagement.com/issues/2017/february-2017-vol-7-no-2/905-lenvima-lenvatinib-approved-in-combination-with-everolimus-for-patients-with-advanced-renal-cell-carcinoma</ext-link>.
- S. Arora, S. Balasubramaniam, W. Zhang, L. Zhang, R. Sridhara, D. Spillman, J. P. Mathai, B. Scott, S. J. Golding, M. Coory, R. Pazdur and J. A. Beaver, FDA Approval Summary: Pembrolizumab plus lenvatinib for endometrial carcinoma, a collaborative international review under project orbis, <em>Clin. Cancer Res.</em> <bold>26</bold> (2020) 5062–5067; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1158/1078-0432.CCR-19-3979" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1158/1078-0432.CCR-19-3979</a>">https://doi.org/10.1158/1078-0432.CCR-19-3979</ext-link>
- A. Kawazoe, S. Fukuoka, Y. Nakamura, Y. Kuboki, M. Wakabayashi, S. Nomura, Y. Mikamoto, H. Shima, N. Fujishiro, T. Higuchi, A. Sato, T. Kuwata and K. Shitara, Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial, <em>Lancet Oncol.</em> <bold>21</bold> (2020) 1057–1065; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/S1470-2045(20)30271-0" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/S1470-2045(20)30271-0</a>">https://doi.org/10.1016/S1470-2045(20)30271-0</ext-link>
- J. Capdevila, N. Fazio, C. Lopez, A. Teulé, J. W. Valle, S. Tafuto, A. Custodio, N. Reed, M. Raderer, E. Grande, R. Garcia-Carbonero, P. Jimenez-Fonseca, J. Hernando, A. Bongiovanni, F. Spada, V. Alonso, L. Antonuzzo, A. Spallanzani, A. Berruti, A. La Casta, I. Sevilla, P. Kump, D. Giuffrida, X. Merino, L. Trejo, P. Gajate, I. Matos, A. Lamarca, T. Ibrahim, Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: Results of the Phase II TALENT Trial (GETNE1509), <em>J. Clin. Oncol.</em> <bold>39</bold> (2021) 2304–2312; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1200/JCO.20.03368" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1200/JCO.20.03368</a>">https://doi.org/10.1200/JCO.20.03368</ext-link>
- K. Bajbouj, R. Qaisar, M. A. Alshura, Z. Ibrahim, M. B. Alebaji, A. W. Ani, H. M. Janajrah, M. M. Bilalaga, A. I. Omara, R. S. Abou Assaleh, M. M. Saber-Ayad and A. B. Elmoselhi, Synergistic anti-angiogenic effect of combined VEGFR kinase inhibitors, lenvatinib, and regorafenib: A therapeutic potential for breast cancer, <em>Int. J. Mol. Sci.</em> <bold>23</bold> (2022) Article ID 4408 (10 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3390/ijms23084408" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3390/ijms23084408</a>">https://doi.org/10.3390/ijms23084408</ext-link>
- A.-C. Dubbelman, H. Rosing, C. Nijenhuis, A. D. R. Huitema, M. Mergui-Roelvink, A. Gupta, D. Verbel, G. Thompson, R. Shumaker, J. H. M. Schellens and J. H. Beijnen, Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas, <em>Invest. New Drugs</em> <bold>33</bold> (2015) 233–240; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1007/s10637-014-0181-7" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1007/s10637-014-0181-7</a>">https://doi.org/10.1007/s10637-014-0181-7</ext-link>
- K. Inoue, H. Mizuo, S. Kawaguchi, K. Fukuda, K. Kusano and T. Yoshimura, Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase, <em>Drug Metab. Dispos.</em> <bold>42</bold> (2014) 1326–1333; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1124/dmd.114.058073" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1124/dmd.114.058073</a>">https://doi.org/10.1124/dmd.114.058073</ext-link>
- R. Shumaker, J. Aluri, J. Fan, G. Martinez, G. A. Thompson and M. Ren, Effects of ketoconazole on the pharmacokinetics of lenvatinib (E7080) in healthy participants, <em>Clin. Pharmacol. Drug Dev.</em> <bold>4</bold> (2015) 155–160; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1002/cpdd.140" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1002/cpdd.140</a>">https://doi.org/10.1002/cpdd.140</ext-link>
- K. Vavrová, R. Indra, P. Pompach, Z. Heger and P. Hodek, The impact of individual human cyto-chrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib, <em>Biomed. Pharmacother.</em> <bold>145</bold> (2022) Article ID 112391 (10 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.biopha.2021.112391" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.biopha.2021.112391</a>">https://doi.org/10.1016/j.biopha.2021.112391</ext-link>
- R. Indra, P. Pompach, V. Martínek, P. Takácsová, K. Vavrová, Z. Heger, V. Adam, T. Eckschlager, K. Kopečková, V. M. Arlt and M. Stiborová, Identification of human enzymes oxidizing the anti-thyroid-cancer drug vandetanib and explanation of the high efficiency of cytochrome P450 3A4 in its oxidation, <em>Int. J. Mol. Sci.</em> <bold>20</bold> (2019) Article ID 3392 (22 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3390/ijms20143392" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3390/ijms20143392</a>">https://doi.org/10.3390/ijms20143392</ext-link>
- R. Indra, K. Vavrová, P. Pompach, Z. Heger and P. Hodek, Identification of enzymes oxidizing the tyrosine kinase inhibitor cabozantinib: Cabozantinib is predominantly oxidized by CYP3A4 and its oxidation is stimulated by cyt b5 activity, <em>Biomedicines</em> <bold>8</bold> (2020) Article ID 547 (14 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3390/biomedicines8120547" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3390/biomedicines8120547</a>">https://doi.org/10.3390/biomedicines8120547</ext-link>
- P. Pannucci, J. March, S. L. Cooper, S. J. Hill and J. Woolard, Effects of axitinib and lenvatinib on cardiovascular function and haemodynamic, <em>Cardiovasc. Res.</em> <bold>118</bold> (2022) Article ID cvac066.210 (1 page); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1093/cvr/cvac066.210" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1093/cvr/cvac066.210</a>">https://doi.org/10.1093/cvr/cvac066.210</ext-link>
- Y. Cui, Y. Li, C. Guo, Y. Li, Y. Ma and Z. Dong, Pharmacokinetic interactions between canagliflozin and sorafenib or lenvatinib in rats, <em>Molecules</em> <bold>27</bold> (2022) Article ID 5419 (15 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3390/molecules27175419" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3390/molecules27175419</a>">https://doi.org/10.3390/molecules27175419</ext-link>.
- Y. Cui, Y. Li, L. Fan, J. An, X. Wang, R. Fu and Z. Dong, UPLC-MS/MS method for the determination of lenvatinib in rat plasma and its application to drug-drug interaction studies, <em>J. Pharm. Biomed. Anal.</em> <bold>206</bold> (2021) Article ID 114360 (7 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.jpba.2021.114360" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.jpba.2021.114360</a>">https://doi.org/10.1016/j.jpba.2021.114360</ext-link>.
- S. Talari, A. Vejendla, S. M. Boddapati and J. Kalidindi, LC-MS/MS method development and validation of lenvatinib and its related impurities in rat plasma: Application to a pharmacokinetic study, <em>Curr. Pharm. Anal.</em> <bold>18</bold> (2022) 614–628; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.2174/1573412918666220330004440" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.2174/1573412918666220330004440</a>">https://doi.org/10.2174/1573412918666220330004440</ext-link>
- M. Stiborová, V. Martínek, H. Rýdlová, T. Koblas and P. Hodek, Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers, <em>Cancer Lett.</em> <bold>220</bold> (2005) 145–154; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.canlet.2004.07.036" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.canlet.2004.07.036</a>">https://doi.org/10.1016/j.canlet.2004.07.036</ext-link>
- V. Kotrbová, B. Mrázová, M. Moserová, V. Martínek, P. Hodek, J. Hudeček, E. Frei and M. Stiborová, Cytochrome b5 shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy, <em>Biochem. Pharmacol.</em> <bold>82</bold> (2011) 669–680; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.bcp.2011.06.003" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.bcp.2011.06.003</a>">https://doi.org/10.1016/j.bcp.2011.06.003</ext-link>
- M. Šulc, R. Indra, M. Moserová, H. H. Schmeiser, E. Frei, V. M. Arlt and M. Stiborová, The impact of individual cytochrome P450 enzymes on oxidative metabolism of benzo[a]pyrene in human livers, <em>Environ. Mol. Mutagen.</em> <bold>57</bold> (2016) 229–235; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1002/em.22001" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1002/em.22001</a>">https://doi.org/10.1002/em.22001</ext-link>
- P. Hodek, J. Koblihová, R. Kizek, E. Frei, V. M. Arlt and M. Stiborová, The relationship between DNA adduct formation by benzo[a]pyrene and expression of its activation enzyme cytochrome P450 1A1 in rat, <em>Environ. Toxicol. Pharmacol.</em> <bold>36</bold> (2013) 989–996; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.etap.2013.09.004" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.etap.2013.09.004</a>">https://doi.org/10.1016/j.etap.2013.09.004</ext-link>
- M. Stiborová, H. Dračínská, V. Martínek, D. Svášková, P. Hodek, J. Milichovský, Ž. Hejduková, J. Brotánek, H. H. Schmeiser and E. Frei, Induced expression of cytochrome P450 1A and NAD(P) H:quinone oxidoreductase determined at mRNA, protein, and enzyme activity levels in rats exposed to the carcinogenic azo dye 1-phenylazo-2-naphthol (Sudan I), <em>Chem. Res. Toxicol.</em> <bold>26</bold> (2013) 290–299; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1021/tx3004533" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1021/tx3004533</a>">https://doi.org/10.1021/tx3004533</ext-link>
- M. Martignoni, R. de Kanter, P. Grossi, A. Mahnke, G. Saturno and M. Monshouwer, An in vivo and in vitro comparison of CYP induction in rat liver and intestine using slices and quantitative RT-PCR, <em>Chem. Biol. Interact.</em> <bold>151</bold> (2004) 1–11; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.cbi.2004.10.002" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.cbi.2004.10.002</a>">https://doi.org/10.1016/j.cbi.2004.10.002</ext-link>
- D. E. Ryan, D. R. Koop, P. E. Thomas, M. J. Coon and W. Levin, Evidence that isoniazid and ethanol induce the same microsomal cytochrome P-450 in rat liver, an isozyme homologous to rabbit liver cytochrome P-450 isozyme 3a, <em>Arch. Biochem. Biophys.</em> <bold>246</bold> (1986) 633–644; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/0003-9861(86)90319-X" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/0003-9861(86)90319-X</a>">https://doi.org/10.1016/0003-9861(86)90319-X</ext-link>
- E. L. LeCluyse, Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics, <em>Chem. Biol. Interact.</em> <bold>134</bold> (2001) 283–289; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/S0009-2797(01)00163-6" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/S0009-2797(01)00163-6</a>">https://doi.org/10.1016/S0009-2797(01)00163-6</ext-link>
- P. Hodek, L. Bořek-Dohalská, B. Sopko, M. Šulc, S. Smrček, J. Hudeček, J. Janků and M. Stiborová, Structural requirements for inhibitors of cytochromes P450 2B: Assessment of the enzyme interaction with diamondoids, <em>J. Enzyme Inhib. Med. Chem.</em> <bold>20</bold> (2005) 25–33; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1080/14756360400024324" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1080/14756360400024324</a>">https://doi.org/10.1080/14756360400024324</ext-link>
- C. S. Yang, Y. Y. Tu, D. R. Koop and M. J. Coon, Metabolism of nitrosamines by purified rabbit liver cytochrome P-450 isozymes, <em>Cancer Res.</em> <bold>45</bold> (1985) 1140–1145.
- M. Stiborová, L. Borek-Dohalská, D. Aimová, V. Kotrbová, K. Kukacková, K. Janouchová, M. Rupertová, H. Ryslavá, J. Hudecek and E. Frei, Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes – similarity between human and rat systems, <em>Gen. Physiol. Biophys.</em> <bold>25</bold> (2006) 245–261.
- M. Martignoni, G. M. M. Groothuis and R. de Kanter, Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction, <em>Expert Opin. Drug Metab. Toxicol.</em> <bold>2</bold> (2006) 875–894; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1517/17425255.2.6.875" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1517/17425255.2.6.875</a>">https://doi.org/10.1517/17425255.2.6.875</ext-link>
- K. J. Wiechelman, R. D. Braun and J. D. Fitzpatrick, Investigation of the bicinchoninic acid protein assay: Identification of the groups responsible for color formation, <em>Anal. Biochem.</em> <bold>175</bold> (1988) 231–237; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/0003-2697(88)90383-1" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/0003-2697(88)90383-1</a>">https://doi.org/10.1016/0003-2697(88)90383-1</ext-link>
- M. D. Burke, S. Thompson, R. J. Weaver, C. R. Wolf and R. T. Mayers, Cytochrome P450 specificities of alkoxyresorufin <em>O</em>-dealkylation in human and rat liver, <em>Biochem. Pharmacol.</em> <bold>48</bold> (1994) 923–936; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/0006-2952(94)90363-8" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/0006-2952(94)90363-8</a>">https://doi.org/10.1016/0006-2952(94)90363-8</ext-link>
- V. Martínek and M. Stiborová, Metabolism of carcinogenic azo dye Sudan I by rat, rabbit, minipig and human hepatic microsomes, <em>Collect. Czechoslov. Chem. Commun.</em> <bold>67</bold> (2002) 1883–1898; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1135/cccc20021883" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1135/cccc20021883</a>">https://doi.org/10.1135/cccc20021883</ext-link>
- M. A. Correia, Human and rat liver cytochromes P450: functional markers, diagnostic inhibitor probes, and parameters frequently used in P450 studies, <em>Cytochrome P 450</em> (2005) 619–657.
- M. Stiborová, R. Indra, E. Frei, K. Kopečková, H. H. Schmeiser, T. Eckschlager, V. Adam, Z. Heger, V. M. Arlt and V. Martínek, Cytochrome b 5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine, <em>Monatsh. Chem.-Chem. Mon.</em> <bold>148</bold> (2017) 1983–1991; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1007/s00706-017-1986-9" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1007/s00706-017-1986-9</a>">https://doi.org/10.1007/s00706-017-1986-9</ext-link>
- M. Stiborová, H. Dračínská, J. Mizerovská, E. Frei, H. H. Schmeiser, J. Hudeček, P. Hodek, D. H. Philips and V. M. Arlt, The environmental pollutant and carcinogen 3-nitrobenzanthrone induces cytochrome P450 1A1 and NAD(P)H:quinone oxidoreductase in rat lung and kidney, thereby enhancing its own genotoxicity, <em>Toxicology</em> <bold>247</bold> (2008) 11–22; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.tox.2008.01.018" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.tox.2008.01.018</a>">https://doi.org/10.1016/j.tox.2008.01.018</ext-link>
- A.-C. Dubbelman, C. M. Nijenhuis, R. S. Jansen, H. Rosing, H. Mizuo, S. Kawaguchi, D. Critchley, R. Shumaker, J. H. Schellens and J. H. Beijnen, Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison, <em>Invest. New Drugs</em> <bold>34</bold> (2016) 300–318; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1007/s10637-016-0342-y" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1007/s10637-016-0342-y</a>">https://doi.org/10.1007/s10637-016-0342-y</ext-link>
- E. L. LeCluyse, Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics, <em>Chem. Biol. Interact.</em> <bold>134</bold> (2001) 283–289; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/S0009-2797(01)00163-6" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/S0009-2797(01)00163-6</a>">https://doi.org/10.1016/S0009-2797(01)00163-6</ext-link>
- A. D. Rodrigues, Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes, <em>Biochem. Pharmacol.</em> <bold>57</bold> (1999) 465–480; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/s0006-2952(98)00268-8" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/s0006-2952(98)00268-8</a>">https://doi.org/10.1016/s0006-2952(98)00268-8</ext-link>
- K. Inoue, H. Mizuo, S. Kawaguchi, K. Fukuda, K. Kusano and T. Yoshimura, Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase, <em>Drug Metab. Dispos.</em> <bold>42</bold> (2014) 1326–1333; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1124/dmd.114.058073" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1124/dmd.114.058073</a>">https://doi.org/10.1124/dmd.114.058073</ext-link>
- Y. Shao, X. Yin, D. Kang, B. Shen, Z. Zhu, X. Li, H. Li, L. Xie, G. Wang and Y. Liang, An integrated strategy for the quantitative analysis of endogenous proteins: A case of gender-dependent expression of P450 enzymes in rat liver microsome, <em>Talanta</em> <bold>170</bold> (2017) 514–522; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.talanta.2017.04.050" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.talanta.2017.04.050</a>">https://doi.org/10.1016/j.talanta.2017.04.050</ext-link>
- D. J. Waxman, J. J. Morrissey and G. A. LeBlanc, Female-predominant rat hepatic P-450 forms j (IIE1) and 3 (IIA1) are under hormonal regulatory controls distinct from those of the sex-specific P-450 forms, <em>Endocrinology</em> <bold>124</bold> (1989) 2954–2966; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1210/endo-124-6-2954" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1210/endo-124-6-2954</a>">https://doi.org/10.1210/endo-124-6-2954</ext-link>
- Y. Asaoka, H. Sakai, J. Sasaki, M. Goryo, T. Yanai, T. Masegi and K. Okada, Changes in the gene expression and enzyme activity of hepatic cytochrome P450 in juvenile Sprague-Dawley rats, <em>J. Vet. Med. Sci.</em> <bold>72</bold> (2010) 471–479; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1292/jvms.09-0397" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1292/jvms.09-0397</a>">https://doi.org/10.1292/jvms.09-0397</ext-link>
- M. Endo, Y. Takahashi, Y. Sasaki, T. Saito and T. Kamataki, Novel gender-related regulation of CYP2C12 gene expression in rats, <em>Mol. Endocrinol.</em> <bold>19</bold> (2005) 1181–1190; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1210/me.2004-0063" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1210/me.2004-0063</a>">https://doi.org/10.1210/me.2004-0063</ext-link>
- S. S. Sundseth, J. A. Alberta and D. J. Waxman, Sex-specific, growth hormone-regulated transcription of the cytochrome P450 2C11 and 2C12 genes, <em>J. Biol. Chem.</em> <bold>267</bold> (1992) 3907–3914; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/S0021-9258(19)50612-3" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/S0021-9258(19)50612-3</a>">https://doi.org/10.1016/S0021-9258(19)50612-3</ext-link>
- H. Hammer, F. Schmidt, P. Marx-Stoelting, O. Pötz and A. Braeuning, Cross-species analysis of hepatic cytochrome P450 and transport protein expression, <em>Arch. Toxicol.</em> <bold>95</bold> (2021) 117–133; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1007/s00204-020-02939-4" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1007/s00204-020-02939-4</a>">https://doi.org/10.1007/s00204-020-02939-4</ext-link>
- Y. Yamazoe, N. Murayama, M. Shimada, K. Yamauchi, K. Nagata, S. Imaoka, Y. Funae and R. Kato, A sex-specific form of cytochrome P-450 catalyzing propoxycoumarin <em>O</em>-depropylation and its identity with testosterone 6β-hydroxylase in untreated rat livers: reconstitution of the activity with microsomal lipids, <em>J. Biochem.</em> (Tokyo) <bold>104</bold> (1988) 785–790; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1093/oxfordjournals.jbchem.a122550" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1093/oxfordjournals.jbchem.a122550</a>">https://doi.org/10.1093/oxfordjournals.jbchem.a122550</ext-link>
- C. R. Jones and R. A. Lubet, Induction of a pleiotropic response by phenobarbital and related compounds: Response in various inbred strains of rats, response in various species and the induction of aldehyde dehydrogenase in Copenhagen rats, <em>Biochem. Pharmacol.</em> <bold>44</bold> (1992) 1651–1660.
- Rat Genome Database, Retrieved August 14, 2023, from <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://rgd.mcw.edu/">https://rgd.mcw.edu/</ext-link>
- N. Shimojo, T. Ishizaki, S. Imaoka, Y. Funae, S. Fuji and K. Okuda, Changes in amounts of cyto-chrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes, <em>Biochem. Pharmacol.</em> <bold>46</bold> (1993) 621–627; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/0006-2952(93)90547-A" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/0006-2952(93)90547-A</a>">https://doi.org/10.1016/0006-2952(93)90547-A</ext-link>
- K. Inoue, N. Asai, H. Mizuo, K. Fukuda, K. Kusano and T. Yoshimura, Unique metabolic pathway of [14C] lenvatinib after oral administration to male cynomolgus monkey, <em>Drug Metab. Dispos.</em> <bold>40</bold> (2012) 662–670; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1124/dmd.111.043281" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1124/dmd.111.043281</a>">https://doi.org/10.1124/dmd.111.043281</ext-link>
- K. Iwanaga, T. Honjo, M. Miyazaki and M. Kakemi, Time-dependent changes in hepatic and intestinal induction of cytochrome P450 3A after administration of dexamethasone to rats, <em>Xenobiotica</em> <bold>43</bold> (2013) 765–773; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3109/00498254.2012.761741" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3109/00498254.2012.761741</a>">https://doi.org/10.3109/00498254.2012.761741</ext-link>
- J. Asteinza, R. Camacho-Carranza, R. E. Reyes-Reyes, V. Dorado-González and J. J. Espinosa-Aguirre, Induction of cytochrome P450 enzymes by albendazole treatment in the rat, <em>Environ. Toxicol. Pharmacol.</em> <bold>9</bold> (2000) 31–37; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/S1382-6689(00)00059-4" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/S1382-6689(00)00059-4</a>">https://doi.org/10.1016/S1382-6689(00)00059-4</ext-link>
- S. Safe, Molecular biology of the Ah receptor and its role in carcinogenesis, <em>Toxicol. Lett.</em> <bold>120</bold> (2001) 1–7; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/S0378-4274(01)00301-0" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/S0378-4274(01)00301-0</a>">https://doi.org/10.1016/S0378-4274(01)00301-0</ext-link>
- M. Degawa, S. Miura, K. Yoshinari and Y. Hashimoto, Altered expression of hepatic CYP1A enzymes in rat hepatocarcinogenesis, <em>Jpn. J. Cancer Res.</em> <bold>86</bold> (1995) 535–539; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1111/j.1349-7006.1995.tb02431.x" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1111/j.1349-7006.1995.tb02431.x</a>">https://doi.org/10.1111/j.1349-7006.1995.tb02431.x</ext-link>
- J. P. Chovan, S. C. Ring, E. Yu and J. P. Baldino, Cytochrome P450 probe substrate metabolism kinetics in Sprague Dawley rats, <em>Xenobiotica</em> <bold>37</bold> (2007) 459–473; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1080/00498250701245250" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1080/00498250701245250</a>">https://doi.org/10.1080/00498250701245250</ext-link>
- G. Mikus and K. I. Foerster, Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity, <em>Transl. Cancer Res.</em> <bold>6</bold> (2017) s1592-s1599; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/<a href="https://doi.org/10.21037/tcr.2017.09.10" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.21037/tcr.2017.09.10</a>">http://doi.org/<a href="https://doi.org/10.21037/tcr.2017.09.10" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.21037/tcr.2017.09.10</a></ext-link>
- Q. Lin, Y. Li, X. Lu, R. Wang, N. Pang, R. Xu, J. Cai and G. Hu, Characterization of genetic variation in CYP3A4 on the metabolism of cabozantinib in vitro, <em>Chem. Res. Toxicol.</em> <bold>32</bold> (2019) 1583–1590; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1021/acs.chemrestox.9b00100" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1021/acs.chemrestox.9b00100</a>">https://doi.org/10.1021/acs.chemrestox.9b00100</ext-link>
- G. M. Amaya, R. Durandis, D. S. Bourgeois, J. A. Perkins, A. A. Abouda, K. J. Wines, M. Mohamud, S. A. Starks, R. N. Daniels and K. D. Jackson, Cytochromes P450 1A2 and 3A4 catalyze the metabolic activation of sunitinib, <em>Chem. Res. Toxicol.</em> <bold>31</bold> (2018) 570–584; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1021/acs.chemrestox.8b00005" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1021/acs.chemrestox.8b00005</a>">https://doi.org/10.1021/acs.chemrestox.8b00005</ext-link>
- K. D. Hardy, M. D. Wahlin, I. Papageorgiou, J. D. Unadkat, A. E. Rettie and S. D. Nelson, Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: Induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells, <em>Drug Metab. Dispos.</em> <bold>42</bold> (2014) 162–171; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1124/dmd.113.054817" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1124/dmd.113.054817</a>">https://doi.org/10.1124/dmd.113.054817</ext-link>
- D. Mckillop, A. D. McCormick, A. Millar, G. S. Miles, P. J. Phillips and M. Hutchison, Cytochrome P450-dependent metabolism of gefitinib, <em>Xenobiotica</em> <bold>35</bold> (2005) 39–50; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1080/00498250400026464" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1080/00498250400026464</a>">https://doi.org/10.1080/00498250400026464</ext-link>
- C. Lu and A. P. Li, Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog, <em>Chem. Biol. Interact.</em> <bold>134</bold> (2001) 271–281; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/S0009-2797(01)00162-4" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/S0009-2797(01)00162-4</a>">https://doi.org/10.1016/S0009-2797(01)00162-4</ext-link>
- O. Kuzbari, C. M. Peterson, M. R. Franklin, L. B. Hathaway, E. B. Johnstone, A. O. Hammoud and J. G. Lamb, Comparative analysis of human CYP3A4 and rat CYP3A1 induction and relevant gene expression by bisphenol A and diethylstilbestrol: Implications for toxicity testing paradigms, <em>Reprod. Toxicol.</em> <bold>37</bold> (2013) 24–30; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.reprotox.2013.01.005" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.reprotox.2013.01.005</a>">https://doi.org/10.1016/j.reprotox.2013.01.005</ext-link>
- EMA, Lenvima, Eur. Med. Agency. Text; Retrieved August 21, 2023, from <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima">https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima</ext-link>
- M. Kolarik, R. Indra, V. Adam, Z. Heger, K. Kopeckova, V. M. Arlt and M. Stiborova, Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro, <em>Neuroendocrinol. Lett.</em> <bold>39</bold> (2018) 515–524.
- R. Shumaker, M. Ren, J. Aluri, C. E. Dutcus, C. Rance and C. He, An open-label phase 1 study to determine the effect of lenvatinib on the pharmacokinetics of midazolam, a CYP3A4 substrate, in patients with advanced solid tumors, <em>Eur. J. Drug Metab. Pharmacokinet.</em> <bold>45</bold> (2020) 373–383; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1007/s13318-020-00607-7" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1007/s13318-020-00607-7</a>">https://doi.org/10.1007/s13318-020-00607-7</ext-link>
- A. Mode, R. AhIgren, O. Lahuna and J.-Å. Gustafsson, Gender differences in rat hepaticCYP2C gene expression regulation by growth hormone, <em>Growth Horm. IGF Res.</em> <bold>8</bold> (1998) 61–67; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/S1096-6374(98)80025-7" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/S1096-6374(98)80025-7</a>">https://doi.org/10.1016/S1096-6374(98)80025-7</ext-link>
- D. J. Waxman and T. K. Chang, <em>Hormonal Regulation of Liver Cytochrome P450 Enzymes</em>, in <em>Cytochrome P450</em> (Ed. Ortiz de Montellano) Springer, Boston 2005, pp. 347–376; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1007/0-387-27447-2_9" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1007/0-387-27447-2_9</a>">https://doi.org/10.1007/0-387-27447-2_9</ext-link>
Language: English
Page range: 441 - 459
Accepted on: Jun 20, 2024
Published on: Sep 14, 2024
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2024 Radek Indra, Sandra Jelínková, Katarína Kollárová, Petra Zahumenská, Josef Dvořák, Šárka Dušková, Helena Dračínská, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.